Profile data is unavailable for this security.
About the company
Citius Oncology, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on oncology products. Its LYMPHIR (denileukin diftitox-cxdl) is approved by United States Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (a rare form of non-Hodgkin lymphoma) after at least one prior systemic therapy. LYMPHIR is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology. It works by targeting cells that have IL-2 receptors with a toxin derived from diphtheria bacteria. It directly kills tumor cells by binding to the IL-2 receptors and internalizing the diphtheria toxin directly into the tumor cells, causing them to die. It boosts the body's immune response by reducing the number of regulatory T-cells (Tregs) that suppress the immune system, thereby enhancing the body's ability to fight the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD1.93m
- Incorporated2024
- Employees--
- LocationCitius Oncology Inc420 Lexington Ave, Suite 2446NEW YORK 10017United StatesUSA
- Phone+1 (347) 627-0058
- Fax+1 (302) 531-3150
- Websitehttps://www.tenxkeane.com/
Mergers & acquisitions
Acquired company | CTOR:NAQ since announced | Transaction value |
---|---|---|
Citius Oncology Inc | -88.56% | 675.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vistagen Therapeutics Inc | 970.40k | -33.19m | 83.06m | 41.00 | -- | 0.7925 | -- | 85.59 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
Aclaris Therapeutics Inc | 32.02m | -58.68m | 84.90m | 91.00 | -- | 0.6343 | -- | 2.65 | -0.8267 | -0.8267 | 0.4509 | 1.88 | 0.1614 | -- | 84.70 | 351,824.20 | -29.58 | -47.29 | -32.76 | -53.87 | 42.63 | 44.00 | -183.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Armata Pharmaceuticals Inc | 3.72m | -67.04m | 85.57m | 66.00 | -- | -- | -- | 23.01 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
Clearside Biomedical Inc | 7.52m | -33.46m | 85.96m | 30.00 | -- | -- | -- | 11.42 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Ovid Therapeutics Inc | 567.53k | -29.75m | 86.59m | 40.00 | -- | 0.9739 | -- | 152.57 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
X4 Pharmaceuticals Inc | 563.00k | 17.63m | 87.54m | 93.00 | 6.06 | 0.9251 | 4.85 | 155.48 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
Citius Oncology Inc | 0.00 | 1.93m | 88.42m | -- | 5.12 | 0.1789 | 45.73 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
Medicinova Inc | 1.00m | -8.16m | 88.77m | 13.00 | -- | 1.55 | -- | 88.77 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
Allovir Inc | 0.00 | -140.34m | 89.19m | 112.00 | -- | 0.7411 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Werewolf Therapeutics Inc | 9.28m | -53.73m | 89.59m | 45.00 | -- | 0.8613 | -- | 9.65 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 90.61m | 9.00 | -- | 16.37 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
CytomX Therapeutics Inc | 119.57m | 11.09m | 92.18m | 120.00 | 8.61 | -- | 7.10 | 0.7709 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Ikena Oncology Inc | 1.84m | -66.71m | 93.41m | 18.00 | -- | 0.5776 | -- | 50.66 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
Hillevax Inc | 0.00 | -156.27m | 93.60m | 90.00 | -- | 0.4522 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
Bioatla Inc | 0.00 | -104.56m | 93.77m | 65.00 | -- | 2.99 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Holder | Shares | % Held |
---|---|---|
TD Securities (USA) LLCas of 30 Jun 2024 | 627.18k | 0.88% |
W.R. Berkley Corp. (Investment Portfolio)as of 30 Jun 2024 | 530.50k | 0.74% |
RiverNorth Capital Management LLCas of 30 Jun 2024 | 350.00k | 0.49% |
Mizuho Securities USA LLCas of 30 Jun 2024 | 343.50k | 0.48% |
Glazer Capital LLCas of 30 Jun 2024 | 306.72k | 0.43% |
Westchester Capital Management LLCas of 30 Jun 2024 | 300.00k | 0.42% |
Hudson Bay Capital Management LPas of 30 Jun 2024 | 299.30k | 0.42% |
Logan Stone Capital LLCas of 30 Jun 2024 | 243.16k | 0.34% |
Yakira Capital Management, Inc.as of 30 Jun 2024 | 225.00k | 0.32% |
The Quarry LPas of 30 Jun 2024 | 200.20k | 0.28% |